Rising Pharmaceuticals recalled 4,212 bottles of Furosemide Tablets on January 10, 2026. The recall stems from the discovery of a foreign substance in the medication. Consumers should stop using the product immediately and seek guidance from their healthcare provider.
Presence of Foreign Substance
Consumers and healthcare providers should stop using this product immediately. Contact Graviti Pharmaceuticals Private Limited or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Furosemide Tablets are a prescription medication used to treat fluid retention and swelling caused by heart failure or other medical conditions. Consumers buy this medication to manage their health effectively under their healthcare provider's guidance.
The presence of a foreign substance in the tablets can pose serious health risks. Such contaminants may lead to adverse effects, particularly for patients with underlying health issues.
This recall is not part of a broader industry pattern.
The recall requires immediate action from consumers, potentially disrupting their medication routines and necessitating alternative treatment plans.
The lot number and expiration date can usually be found on the label of the bottle or on the bottom of the packaging.
Expect a refund or replacement process to take approximately 4-6 weeks.
Keep records of your purchase, including receipts and any correspondence regarding the recall.
The recall affects Furosemide Tablets, USP 40 mg, sold in 1,000-tablet bottles. The affected lot number is FUB125042G with an expiration date of May 13, 2027. These products were distributed nationwide in the U.S.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
Graviti Pharmaceuticals Private Limited manufactured Bupropion Hydrochloride Extended-Release Tablets XL 300 mg, distributed nationwide by Rising Pharma Holdings, Inc., in 46,512 bottles. The recall cites failed tablet specifications. Stop using the product immediately and contact the manufacturer or your healthcare provider for guidance.